Partner and Exhibitor Manual

This manual has been designed to answer your pre-event enquiries and assist you in your role as a partner or exhibitor.

Please share this manual with any contractors or colleagues to ensure that they comply with the necessary requirements.

*Please disregard any items that are not relevant to your partner or exhibitor package.

Specifications on the below requirements are outlined throughout this document.

ITEM DUE DATE INSTRUCTIONS
PARTNER PROGRAM
Partner program onboarding form
27 May
Industry networking event for listing
27 May
EXHIBITION
Public liability insurance
27 May
Furtniture ordering
ASAP
Contact Exponet
Booth upgrade
ASAP
Contact Exponet
Fascia
27 June
Delivery of materials to venue
24 - 48 hours prior
Materials picked up from venue
1 August
The venue will provide the delivery label template onsite
 ACKNOWLEDGEMENT AND PROMOTION
Company profile
ASAP
Company logo
ASAP
EDM banner
7 days prior to schedule
App advert
27 June
REGISTRATION
Registration deadline
27 June

MAIN CONTACT

MCI PRIMARY LOGO RGB
ExpoNet

ASM organiser

Jennifa Vo
Project Manager
MCI Australia
07 3858 5400
info@anzchog2022.com.au
www.anzchog2022.com.au

Exhibition builder

Magdalena Jablonski
Exhibition Cordinator
Exponet
02 9645 7000
magdalena@exponet.com.au
www.exponet.com.au

Freight forwarder

Name name
Position
DSV
xx xxxx xxxx
email address
www.dsv.com

ASM

For general ASM information please visit the ANZCHOG website: www.anzchog2022.com

Onboarding form

Please complete industry program onboarding form as required by the deadline indicated in the checklist and deadlines. Failure to do so may result in our inability to provide the appropriate service/s and may result in additional fees.

Deadline: 27 May 2022

You will be required to provide:

  • Session title
  • Synopsis
  • Schedule of presentations e.g.
    • 10:20 – Chair introduction (5 mins)
    • 10:25 – Speaker 1 (15 mins)
    • 10:40 – Speaker 2 (15 mins)
    • 11:55 – Speaker 3 (15 mins)
    • 11:10 – Q&A (25 mins)
  • Chair name and contact details (including bio and photo)
  • Presenter name/s and contact details (including bio and photo)


If you require any assistance with this, please contact us at info@anzchog2022.com

Speaker requirements

Please liaise directly with your nominated speakers and chairs to confirm their availability and requirements.

All speakers and chairs must be registered to be able to attend and present at the session. You can use one of your partnership complimentary registrations to register your speaker for free or you can purchase additional registrations. 

If you are not sure what registration type is most suitable for your speakers, please contact us at info@anzchog2022.com

Speaker presentation

Presentation upload: On the day of presentation, speakers will need to submit their presentation slides onsite to our speaker preparation room where you will be able to go through the slides and rehearse with your speakers.

Speaker setup: Your speaker/s and chair/s will be presenting in your session room at the Sheraton Grand Hyde Park, Sydney. They will have a lectern, stage, microphone, and slide advancer for presentation. The presentation will be pre-loaded to the screen via the speaker’s preparation room.

Room setup: The room will be set up in cabaret style.

Allocated time: All times listed include set-up, presentation and pack-up time. Pre-presentation room access may be available for some timeslots and subject to agreement with the ANZCHOG ASM 2022 organisers.

Presentation template: Download the PPT slides for presentation here.

Live polling

Polling questions must be submitted by 27 June 2022 to the ASM organisers to enable pre-setting in the system.

Polling responses can feature:

  • yes / no;
  • multiple choice; and
  • single choice
Item Shell scheme Space only Description

Complimentary registration

Complimentary exhibitor registrations (Exhibition access, catering, 1 x welcome reception ticket. No session access)

Two (2) per 6sqm
Structure
2.5mh Octanorm structure with white melamine or silver in an aluminium frame.
Fascia panel
Aluminium fascia, 30cm high on all aisle frontages.

Furtniture

Furtinure is not included and can be order directly through Exponet.

Lighting
2x track spotlights per 6spm Lights fixed to the inside front facia.
Power
1x 4amp power outlet, per stand, located in the back corner
Delegate list
Delegate list (first and last name, organisation, country and email. Subject to GDPR and privacy laws)
Lead capture
QR-code lead tracking (app-based scanning)
Exhibitor listing
Logo and 50 word profile listed on the ASM website and app

Public liability insurance

You must hold a current public liability insurance policy for a minimum of AUD 10,000,000.

Deadline: 27 May 2022

Entry to the venue will be denied if you have not provided a copy of this information to the conference managers.

If you haven’t already done so, please upload a copy of your public liability insurance policy to the industry portal no later than 27 May 2022. If you do not hold a current public liability insurance policy, valid in Australia, please contact the conference managers who can arrange a policy on your behalf (fee applies).

The venue and the conference managers shall not be responsible for any loss, damage or injury that may occur to the exhibitor, exhibitor’s employees (public or other) or property from any cause whatsoever prior, during and subsequent to the exhibition. The exhibitor, on contracting for space or an exhibition stand, expressly releases the organisers and the venue from, and agrees to indemnify same against, any and all claims for such direct and indirect loss, damage or injury.

Exhibitors shall indemnify and hold harmless the organisers, venue and their agents from all liability (damage, incident or accident) which might ensue from any cause resulting or connected with the transportation, placing, removal or display of exhibits.

Delegate list

An electronic copy for the delegate list will be provided seven (7) days pre and post conference.

Ordering furniture or requesting a booth upgrade

Furtniture is not included with your exhibition booth. To order furtniture, please contact Exponet.

Materials - delivery and collection

Delivery of materials can only be accepted from 24 – 48 hours prior to the conference commencing.

An outgoing delivery label will be provided onsite, exhibitors must affix this to any items that will be collected via courier post-event.

Delivery and collection address

Sheraton Grand Sydney Hyde Park
Loading Dock – 138 Castlereagh Street
Sydney NSW 2000, AUSTRALIA

Loading Dock
  • Access via 138 Castlereagh Street Sydney
  • Dock Height 3.1m
  • Guest Carpark Height 2m
  • Manned Hours – 0700 – 1600 however outside of this time our banquets team can assist with deliveries
  • No forklift on site but there is a dock leveller and trolleys
  • Dock access leads straight up to back of house Level 2 behind the Grand Ballroom


Back of House Lift Dimensions

  • Door Opening 2.1m x 1.3m
  • Width 1.7m
  • Depth 2.28m
  • Height 2.2m
  • Capacity 1500kg


Couriered Items

  • Please affix the attached label to all items
  • Note we only accept deliveries 24 – 48 hours prior to the conference commences as the dock is a working dock and we simply don’t have the storage space
  • Exhibitors will be provided with outgoing item labels post conference to label their items

Freight forwarding

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Storage

Prior the Symposium

Due to the Sheraton Grand Sydney Hyde Park limited storage facilities, delivery of material can only be accepted 24 – 48 hours prior to conference commencing.

During the Symposium

There will be no onsite storage for boxes and general packing material, please keep packing materials to a minimum so that they can be stored under your table.

After the Symposium

Due to the limited storage arrangements all goods belonging to exhibitors must be claimed and removed from the venue by Monday 1 August 2022.

Exhibition schedule

Date Time Details
Thursday 28 July
0500-1000
Exponet bump in
Thursday 28 July
0700-1000
Custom stand bump in
Thursday 28 July
0900-1000
Booth access for exhibitor set up
Thursday 28 July
1000-1015
Exhibition area cleaned and final touches
Thursday 28 July
1015-1045
Exhibition open - morning tea
Thursday 28 July
1215-1315
Exhibition open - lunch
Thursday 28 July
1445-1515
Exhibition open - afternoon tea
Friday 29 July
1000-1030
Exhibition open - morning tea
Friday 29 July
1200-1300
Exhibition open - lunch 
Friday 29 July
1430-1500
Exhibition open - afternoon tea
Saturday 30 July
1100-1130
Exhibition open - morning tea
Saturday 30 July
1130
Exhibition close
Saturday 30 July
1130-1230
Exhibitor pack down
Saturday 30 July
1230-1430
Custom and shell stand dismantle

*Timing subject to change

Exhibition location

Level 2 Foyer
Sheraton Grand Sydney Hyde Park
161 Elizabeth St
Sydney NSW 2000

Registration

Please make sure you collect your registration items from the registration desk when you arrive onsite, before accessing the exhibition space.

You can collect all of your registration material from the registration desk located in the foyer on level 2.

Access to pre-delivered materials

The venue will transport all goods from the loading dock to your allocated space within the exhibition area.

Unpacking within the exhibition area must take place in your space area and not in the way of another exhibitor’s space.  Aisles must be kept clear at all times and fire exits must not be utilised under any circumstances for storage.

Security

Pre and post Symposium

While every reasonable precaution is taken, the Conference Managers and the venue accept no responsibility for any loss or damage that may occur to persons or property at the exhibition resulting from any cause whatsoever. If you require additional security or a physical presence in the exhibition area, independent security staff dedicated to duty in your exhibition space can be engaged at the exhibitor’s cost. Please contact the Conference Managers for additional security information.

Exhibitors must make provisions for the safeguarding of their goods, materials, equipment and displays at all times.  Please be security conscious. Do not leave wallets, laptops, mobile telephones or any easily portable items unattended, at any time, in your stand. The protection of your property is your responsibility.

During the Symposium

Exhibitors are strongly advised to remove any valuable material (e.g. laptops) or equipment from their booths if personnel are not going to be present at the stand.  Security is the exhibitor’s responsibility if it is required.

Testing and tagging of electrical equipment

All portable electrical equipment, appliances and leads used on the onsite must be tested and tagged in accordance with Australian Standard 3760:2003 and Workplace Health & Safety Legislation. Any electrical equipment found not tested will have to be done immediately or removed from the venue. For safety reasons, double adaptors are not to be used in the venue. It is the exhibitor’s responsibility to ensure that all loose cables are secured to avoid tripping hazards and are in accordance with Australian Standard 3760:2003.

Company profile

Company profile: 

  • Diamond partner: 200 words
  • Gold partner: 150 words
  • Silver partner: 100 words
  • Other sponsors and exhibitors: 50 words
Due date: ASAP

By providing the above, you hereby acknowledge that the information will be used in a variety of digital and print materials.

Company logo

Company logo: High resolution in transparent .png format

Due date: ASAP

By providing the above, you hereby acknowledge that the information will be used in a variety of digital and print materials.

App advertisement specifications

Dimensions: A4
File type: .pdf

Due date: 27 June 2022
EDM banner specifications

Dimensions: 600w x 200h px
File type: High resolution banner in .png or .jpg format

Due date: 7 days prior to schedule

Registration entitlements

As a sponsor and/or exhibitor, you are entitled to several complimentary registrations as per your sponsorship package/number of booths confirmed. Please refer to your confirmation email as different levels of sponsors are entitled to a variety of registration discounts.

Complimentary industry partner

Industry partner registration includes:

  • Access to all scientific sessions
  • Access to exhibition and poster displays
  • Morning/afternoon teas and lunches as per the program
  • 1x ticket to the welcome reception on Thursday 28 July
  • 1x ticket to the gala dinner on Friday 29 July

Complimentary exhibitor

Exhibitor registration includes:

  • Access to exhibition and poster displays
  • Morning/afternoon teas and lunches as per the program
  • 1x ticket to the welcome reception on Thursday 28 July

Registering

To access complimentary industry partner and exhibitor registration please enter the code: CHOG22SPEX during the registration process. If you are unable to locate this, please contact info@anzchog2022.com for assistance.

Deadline: Monday 27 June 2022

ANZCHOG ASM 2022

Please visit the ASM website for general ASM information.

www.anzchog2022.com

VENUE

SHERATON GRAND SYDNEY HYDE PARK

161 Elizabeth Street
Sydney NSW 2000
W: www.sheratongrandsydney.com

The Australian & New Zealand Childrens Haematology/Oncology Group’s Annual Scientific Meeting 2022 will be held at the Sheraton Grand Sydney Hyde Park. which combines the latest in technology and style in Sydney’s CBD to create refined spaces ideal for the 2022 ASM.

Sheraton Grand Sydney Hyde Park is one of Sydney’s most desirable event destinations. Natural light, high-speed Wi-Fi, outdoor terraces and dedicated concierge services ensure productive meetings any time of year.

The expert culinary team crafts custom menus for the meeting. With five on-site venues and in-room dining, you’re never far from a delicious meal or post-meeting snack.

Centrally located in the heart of Sydney’s retail and business districts, Sheraton Grand Sydney is the perfect launch pad for exploring Sydney’s iconic attractions, open-air shopping malls, fine restaurants, cafes, bars and destinations that define this vibrant city.

DELEGATE LIST

An electronic copy for the delegate list will be provided seven (7) days pre and post conference.

CATERING

Morning tea, lunch and afternoon tea will be served daily in the exhibition.

You may NOT bring any outside food or beverages into the venue for consumption during the ASM, unless agreed by the hotel in writing and in advance of the ASM. If exhibitors provide external catering on the day without prior approval from the venue this will be refused.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

TERMS & CONDITIONS

The following terms and conditions apply to your contract to partner and/or exhibit at the Australia and New Zealand Children’s Haematology and Oncology Group Annual Scientific Meeting 2022.

Things you need to know
  • You (partnering/sponsoring/exhibiting organisation) by completing the sponsorship booking form or the exhibition booking form accept these Terms and Conditions.
  • We/Us (MCI ABN 76 108 781 988) representing the Organising Committee and the Host Body do not accept responsibility for any errors, omissions or changes.
  • Details may change without notice. Please refer to the website (https://anzchog2021.com/) for the latest information on ANZCHOG ASM 2022.
Financial facts
  • Phone or unpaid bookings will not be accepted.
  • We will issue a tax invoice which is payable within 14 days. If you miss the payment date, any time dependent discounts will be forfeited— i.e. you will be billed at the next highest level (early rate to standard, etc.).
  • You will not receive any sponsorship or exhibition entitlements, including allocation of booth location (allocated in order of sponsorship/exhibition level) until all monies have been paid.
  • All prices are quoted in Australian dollars and include GST.
  • Payments can be made via electronic funds transfer (EFT).
  • If you pay by electronic funds transfer you agree to pay any bank charges and must include these in the amount you transfer.
  • If you pay via credit card a processing fee may be charged.
Cancellation
  • You must notify us in writing if you need to cancel.
  • Cancellations received prior to 1 April 2022 will be refunded 50% of the total investment amount
  • Cancellations made after this date will not be refunded.
  • Your non-payment does not cancel your contractual obligations to us.
  • No exhibitor shall occupy allocated space until all monies owing to the organiser by the exhibitor are paid in full.


IN THE UNLIKELY CASE THAT THE EVENT CANCELS

  • You will receive a full refund in case of the event cancelling. If the event moves to another date, then you will be offered the opportunity for a full refund if the new date does not work for your organisation.


IN THE UNLIKELY CASE THAT THE EVENT POSTPONES OR CHANGES FORMAT SIGNIFICANTLY FROM WHAT IS OUTLINED IN THIS PROSPECTUS

  • The extent of refunds will be a matter for the Host Organisation (the underwriter) to decide.
You and your staff onsite
  • All exhibition staff must be registered online—i.e. complimentary exhibitor/sponsor registration, or by purchasing additional exhibitor/sponsor staff registrations.
Print + promotional entitlements
  • Logos and other printed material may, at our sole discretion, be reproduced in colour (where possible), OR the nominated meeting spot colour/s OR mono depending on the method of production.
  • The sponsor must provide suitable material to meet our publication requirements and deadlines.
  • Please provide all material at 300 DPI at 100% in jpeg (preferred for website) AND eps (preferred for print) format including, where possible, RGB or Pantone colour equivalents.
  • Where applicable, advertisements are to be supplied by the sponsor.
  • No print or web recognition will be given unless payment terms have been met.
Non-sponsored functions
  • To seek approval to host an un-endorsed but approved satellite function, please share with the conference secretariat the following details for review and approval by the ASM organisers:
    • Function name
    • Location
    • Date/time
    • Expected attendee numbers
    • Function objectives/content summary
  • Proceeding with running unauthorised function in competition with the ASM will be seen has hosting a pirate symposium.
Privacy statement

Your name and contact information, including electronic address, may be used by parties directly related to the event such as the organisers and approved stakeholders, for relevant purposes such as promotion, networking, and administration of this, and future events of this type. If you do not consent, please advise us. In addition, your name, organisation, and country/state of origin may be published on the delegate list which is provided to delegates, exhibitors, and partners at the event. If you do not wish your details to be included in this list, please contact us.

Echo Therapeutics is an Australian Pharmaceutical and Medical Technology Company, specialising in products and services for the Hospital sector in Australia and New Zealand. Our aim is to gain deep customer insights to resolve unmet needs.

Partnering with global and local groups, we will build complementary suites of products and services for the ANZ markets that will have a meaningful impact on our customers and patients lives.

Our goal is to work with ANZCHOG to improve access to medicines in paediatric oncology.

Vencare Medical

ECP made EASY! Flexible two-step ECP that works for you! info@vencaremedical.com.au

Leukaemia & Blood Cancer New Zealand (LBC) is New Zealand’s national charity dedicated to supporting patients, and their families/whānau, living with a blood cancer or a serious blood condition.

At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases.

Through bold and transformative science, we’re driving innovation that has the potential to become the next generation of life-changing medicines. Our ambition is evident in our mission. Because the impossible is not impossible. It’s what’s next.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Novartis has more than 60 years’ history in Australia and employ around 600 associates across its two divisions.

A/Prof Jordan Hansford

Women’s and Children’s Hospital Adelaide

Jordan is a mid-career clinician specializing in the treatment of paediatric brain tumours. He has a long-standing interest in cancer genetics post the completion of his Master’s of Science in Cancer Genetics at Queen’s University, Canada. Upon the completion of his clinical training and admission to fellowship, he relocated to Melbourne where he led the team’s neuro-oncology and clinical research teams. Most recently he has relocated to Adelaide where he is developing a Neuro-Oncology research program at SAHMRI/SAiGENCI and the new Bragg Proton Radiotherapy Centre. He is currently the chair of the ANZCHOG brain group.

Proudly supported by

Jazz Pharmaceuticals is a global Biopharmaceutical Company whose purpose is to transform the lives of patients and their families through innovation. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options so they can live their lives more fully.

We have a diverse portfolio of marketed medicines and novel product candidates, from early- to latestage development, in Neuroscience and Haematology/Oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science.

Jazz Pharmaceuticals has employees around the globe including Australia and New Zealand, serving patients in nearly 75 countries

Medical Information
Phone: 1800577422
Email: medinfo-apac@jazzpharma.com

Adverse event
Phone: 1800577422
Email: AEReporting@jazzpharma.com


To report a Product Complaint, please email:
productcomplaints@jazzpharma.com

For more than 20 years, Illumina has aspired to improve human health by unlocking the power of the genome. As we move towards precision medicinein pediatric cancer, we have only just begun to discover the true impact of genomics. Learn how Illumina technologies is enabling novel insights into childhood cancer risk and treatment. Visit: https://sapac.illumina.com/destination/Precision-Medicine-in-Pediatric-Cancers.html

eviQ and eviQ Education are programs of the Cancer Institute NSW, a state government cancer control agency. Both programs have a national target audience and an international reach.

eviQ provides free online evidence-based, consensus driven cancer treatment protocols and information for use at the point of care. eviQ is developed for the Australian context and supports health professionals in the delivery of cancer treatments.

eviQ Education provides free, evidence-based cancer eLearning resources for health professionals.

BD is one of the largest global medical technology companies in the world and is advancing the world of healthTM by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.

Our history
The Kids’ Cancer Project is an independent national charity supporting childhood cancer research. Since 1993, the charity has contributed more than $50 million dollars to scientific research projects to help children with many different types of cancer.

Our Goal
Mission: To support bold scientific research that has the greatest chance of clinical success in the improvement of treatments of childhood cancers.

Vision: One hundred per cent survival for children with cancer while eradicating the harmful impacts treatment can bring.

What we stand for
Science: We believe the only way to improve outcomes for kids with cancer is through advances in medical research.

Solutions: Our research priorities reflect our focus on finding better treatments, building research capabilities and supporting survivorship programs.

Survival: Our founder, Col Reynolds OAM, made a promise
to never give up until a cure is found.

The Robert Connor Dawes (RCD) Foundation was created in June 2013 in the memory of Robert ‘Connor Dawes’ who lost his 16-month battle with an ependymoma brain tumour at just 18 years of age. The RCD Foundation works to support brain matters projects in the areas of research, care and development – to fund the science to fight paediatric brain cancer and support patients in the meantime.

The Foundation operates in Australia and the US, and to date has invested $3.45M into paediatric brain cancer research, funding basic science and translational projects, as well as capacity building grants through fellowships, scholarships and travel grants. It has also leveraged another $10M, leading collaborative research initiatives. In addition to funding and partnering with Australian research institutes and Foundations, RCD is also active member of the Child’s Brain Tumour Network (CBTN), Paediatric Neuro-Oncology Consortium (PNOC) and the Collaborative Ependymoma Research Network (CERN). We leverage our research investments through partnering with like-minded and passionate organisations to continue to battle paediatric brain cancer.

Breakthroughs That Change Patients’ Lives: Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and significantly improve lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Servier is a privately owned pharmaceutical company, governed by a non-profit foundation that is committed to therapeutic progress to serve patient needs. Servier has a long-standing commitment to research and development.

Worldwide approximately 25% of branded product turnover is reinvested into research and development through the Servier Foundation, with half of that investment dedicated to research to help fight cancer.
Servier has significant investment in new products in early development in the areas of Oncology and Haematology with broad research and development platforms in cancer cell apoptosis and immuno-oncology. Servier Australia is also home to the Asia-Pacific clinical trial hub.
Servier is proud to support innovative partnering programs with world class institutions including WEHI in Australia to further advance scientific understanding in the area of oncology. For further information see the website www.servier.com.au

Servier Australia’s oncology products include Oncaspar (pegaspargase), Lonsurf® (trifluridine/tipiracil) and Onivyde® (nanoliposomal irinotecan as sucrosofate).

MISSION: WE CHANGE LIVES, PATIENT BY PATIENT

At EUSA we are committed to transforming the lives of people affected by cancer or rare disease, globally.

We continuously strive to uncover opportunities which address gaps across adult and paediatric care – through development opportunities, acquiring, and in-licensing therapies.

Helping the people with few or no options available is at the heart of everything we do at EUSA. Every day, we are proud to make a difference – building a company around our people, our values, and our mission.

We see a need. We work together. We don’t give up.

Bayer is a global life science company with expertise in healthcare and agriculture. The company has had a presence in Australia since 1925 and has a long-term commitment to the health and nutrition of all Australians and New Zealanders. As people live longer and the population continues to grow both locally and beyond, Bayer is one of the few companies that takes a comprehensive view of these issues. Guided by our purpose – Science for a better life – we apply our global scientific expertise in healthcare and agriculture to deliver innovations locally to help people and the planet thrive.

Bayer employs almost 900 people across Australia and New Zealand and is dedicated to servicing the needs of rural and remote communities. Bayer embraces and encourages its employees’ unique identities and advances a culture of inclusion and diversity across gender, LGBTQIA+, generations, disability and race.

For further information visit www.bayer.com.au

Dr Robert Battisti

Children’s Hospital Westmead

Dr Battisti is a Clinical Psychologist and Researcher at the Cancer Centre for Children at the Children’s Hospital at Westmead, and an Honorary Research Associate at the University of Sydney. Dr Battisti completed his PhD at the University of Wollongong and a postdoctoral position with the National Drug and Alcohol Research Centre (NDARC) at the University of New South Wales in partnership with the Brain and Mind Centre at the University of Sydney. Dr Battisti is also on the Board of Directors for the Australian Clinical Psychology Association (ACPA). His clinical background is in child, adolescent and young adult (AYA) psychology as well as parenting psychology, with expertise in paediatric cancer including childhood cancer survivorship.

Annabel Crabb

ABC Journalist

Annabel Crabb is one of Australia’s most beloved journalists. She is an ABC writer and presenter who has covered Australian politics for 20 years but also is nationally well-known for her insightful and humorous analysis on gender and current affairs. 

Annabel recently created and presented the ground breaking Ms Represented, unearthing stories from the 100 years of women in Australian parliaments. For the ABC, she has also devised and presented six seasons of the enormously popular Kitchen Cabinet, and “The House with Annabel Crabb – the fly-on-the-wall documentary on Australian Parliament.” She also presents the ABC’s hit culinary history series Back In Time For Dinner, and co-stars in Tomorrow Tonight with Charlie Pickering.

With friend and ABC colleague Leigh Sales, Australia’s pre-eminent current affairs journalist, Annabel hosts the top-rating podcast Chat 10 Looks 3. Their first book together, Well Hello, was published in September 2021.

Annabel is an avid baker and proud mother of three.

Prof Marcus Vowels

Professor Vowels is a renowned early leader of the paediatric oncology and haematology disciplines in Australia. Professor Vowels established the first bone marrow transplant program in Australia at the then Prince of Wales Children’s Hospital, now Sydney Children’s Hospital in Randwick, NSW. Professor Vowels established the Australian Cord Blood Bank and was a founding trustee of the Australian Cord Blood Foundation. Professor Vowels has over 100 peer reviewed publications, he was the founding member of a number of editorial boards of discipline specific journals and is the author of multiple book chapters. Professor Vowels was the President of the Australian and New Zealand Children’s Cancer Study Group from 1990 to 1994, and was awarded a Member of the Order of Australia (AM) for his service to medicine, particularly in the fields of childhood leukaemia and cancer.

Prof Paul Monagle

University of Melbourne

Professor Monagle is an internationally renowned paediatric haematologist and haemato-pathologist. He is a Professor of Paediatrics at the University of Melbourne, a clinical Haematologist at the Kids Cancer Centre, Sydney Children’s Hospital, and an Honorary Fellow and Group Leader in Haematology Research at the Murdoch Children’s Research Institute. Professor Monagle is a world expert on thrombosis and coagulation, with over 300 publications in the field of paediatric haematology. His research group holds multiple NHMRC grants and is currently leading work into COVID-19 associated thrombosis. Professor Monagle was awarded the Outstanding Research Award in Paediatric Cardiology by the American Heart Association in 2008, and delivered the Barry Firkin Oration for the Thrombosis & Haemostasis Society of Australia and New Zealand in 2018. He has played a key role in designing multiple international multi-centre trials, and been an invited speaker at haematology conferences across the globe.

Dr Robert Battisti

Children’s Hospital Westmead

DR ROB BATTISTI | CLINICAL PSYCHOLOGIST | BPSYCH (HONS), PhD (CLINICAL PSYCHOLOGY) | FACPA | LEUT RAN

Rob Battisti is a Senior Clinical Psychologist and head of Psycho-oncology at the Cancer Centre for Children at the Children’s Hospital at Westmead and a Clinical Director at Mind Plasticity, a large multi-disciplinary mental health practice in Sydney. He is passionate about delivering evidence-based therapies and overcoming some of the traditional barriers that restrict people from accessing top quality care via team care arrangements. A key focus of his work is mental health service development, including policy, governance and clinical training. His goal in children’s cancer services is to ensure that mental wellness, education and future quality of life are placed firmly in the treatment mix.

Rob completed his PhD at the University of Wollongong and a postdoctoral position with the National Drug and Alcohol Research Centre (NDARC) at the University of New South Wales in partnership with the Brain and Mind Centre (BMC) at the University of Sydney. He has worked in and around Sydney for many years and has professional affiliations with organisations such as the BMC, headspace and St Vincent’s Private Hospital. He has additionally served on the Board of Directors for the Australian Clinical Psychology Association (ACPA) of which he is a Fellow member.

Rob has expertise in working with individuals and families with more complex needs and in multi-disciplinary care arrangements. His clinical background is in child, adolescent and young adult (AYA) psychology as well as parenting psychology, with expertise in cancer and other areas of health psychology, addiction, and psychiatric comorbidity (i.e. multiple diagnoses).

Rob also consults to organisations on preventative mental health and is a Lieutenant Psychologist with the Royal Australian Navy.

Dr Justin Baker

St Jude Children’s Research Hospital

Dr Baker is the Division Chief of Quality of Life and Palliative Care at St. Jude Children’s Research Hospital, Memphis, TN, USA. He is trained in paediatric haematology/oncology, as well as Hospice and Palliative Medicine. Dr Baker is a world leader in paediatric palliative care and quality of life, with over 100 publications in the field. His research focuses on integrating palliative care into the ongoing care of children with cancer, the ethical consideration of early phase trials, and paediatric palliative care in developing countries. He was awarded the AAHPM Inspirational Leader in Hospice and Palliative Medicine in 2014, and the St. Jude Communicator of the Year in 2017. Dr Baker has led the development of guidelines in paediatric palliative care and quality of life that have been implemented in centres throughout the world, and has been an invited speaker at paediatric oncology and palliative care conferences across the globe.

Proudly supported by

A/Prof Yasmin Jayasinghe

The Royal Children’s Hospital Melbourne

AProf Yasmin Jayasinghe (FRANZCOG, PhD) is a paediatric gynaecologist , Director of the Oncofertility Program at The Royal Children’s Hospital Melbourne and the Australian representative on the Practice Committee of the global Oncofertility Consortium.  She is founding Chair of the Australian New Zealand Consortium in Paediatric Oncofertility (ANZCO), and is Principal Investigator of the binational ANZCO clinical trials network driven by ANZCHOG champions, who were recently awarded  a $3million MRFF for ‘Life Saving and Job Creating Medical Research’. She was founding chair of the Fertility Preservation Taskforce in Victoria in 2012, who in partnership with consumers pioneered Australia’s first ethically governed paediatric oncofertility program, oncofertility registry (scaled up to the Future Fertility Registry by A Anazodo), and oncofertility nurse navigators. The taskforce have been recognized as finalists in: the Vic Health Awards for facilitating equitable access to oncofertility care; the Australian Nurse of the Year awards for nurse navigation; and three statewide Young Achiever Awards for oncofertility innovation. AProf Jayasinghe has received many honours and in 2021 was a national finalist for the Australian Human Rights Medal for pioneering the protection of the reproductive rights of children.

Join the ANZCHOG ASM mailing list

Stay informed with the latest updates
* indicates required